Back to Search
Start Over
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).
- Source :
- Journal of Clinical Medicine; Feb2019, Vol. 8 Issue 2, p200, 1p
- Publication Year :
- 2019
-
Abstract
- Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly desirable. This article gives an overview on the state-of-the art of preclinical and clinical studies on suitable target antigens for CAR T cell therapy in AML patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20770383
- Volume :
- 8
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Journal of Clinical Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 135936764
- Full Text :
- https://doi.org/10.3390/jcm8020200